About Eli Lilly & Co. 
Eli Lilly & Co.
Pharmaceuticals & Biotechnology
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Company Coordinates 
Company Details
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr INDIANAPOLIS IN : 46285-0001
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 280 Schemes (29.65%)
Foreign Institutions
Held by 763 Foreign Institutions (13.43%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. David Ricks
Chairman of the Board, President, Chief Executive Officer
Mr. Juan Luciano
Lead Independent Director
Mr. Raul Alvarez
Independent Director
Dr. Katherine Baicker
Independent Director
Dr. Carolyn Bertozzi
Independent Director
Mr. Michael Eskew
Independent Director
Revenue and Profits:
Net Sales:
15,558 Million
(Quarterly Results - Jun 2025)
Net Profit:
5,660 Million
Pharmaceuticals & Biotechnology
USD 699,433 Million (Large Cap)
47.00
NA
0.00%
1.99
93.61%
38.28






